Core Viewpoint - Sanyuan Biotech is facing multiple dynamics including the final ruling of anti-dumping duties in the U.S., progress on the allulose project, and the promotion of new products [1] Group 1: Stock Recent Trends - The U.S. Department of Commerce has announced a final ruling on anti-dumping and countervailing investigations regarding Chinese erythritol products, with Sanyuan Biotech facing a comprehensive execution tax rate of 93.58% for exports to the U.S. This ruling will take effect upon publication in the Federal Register and may have a lasting impact on the company's U.S. market operations [2] - The European Union will impose a 156.7% anti-dumping tax on Chinese erythritol starting January 2025, lasting for five years. The company has responded by launching blended products, indicating that the impact of this event may persist [2] Group 2: Company Project Progress - The company's annual production project for 20,000 tons of allulose has completed the construction of the main engineering and equipment installation for the remaining 10,000 tons of capacity. The next steps will involve organizing environmental assessments and gradually advancing production. This project aims to enrich the product portfolio, but the production schedule and benefits are subject to approval processes and market demand [3] Group 3: Business Development Status - Sanyuan Biotech is continuously providing samples of Reb M to domestic and international potential customers and conducting application experiments. Some customers have already incorporated it into their reduced-sugar product formulations. Tagatose, as a key new functional sugar, is in a critical phase of market promotion and industrial application [4] Group 4: Company Status - The company will hold a board meeting on February 4, 2026, to review the proposal for convening the first extraordinary shareholders' meeting of 2026, with further arrangements to be announced [5]

Core Viewpoint - The final ruling on anti-dumping and countervailing duties ("double anti") against Chinese erythritol products has been announced, with the leading company, Sanyuan Biotech, facing a maximum combined tax rate of 93.58%, significantly impacting its market competitiveness in the U.S. [1][2] Group 1: Tax Rates and Impact - Sanyuan Biotech has been assigned a countervailing duty rate of 8.63% and an anti-dumping duty rate of 84.95%, leading to a total tax rate of 93.58% [1][2] - The company did not qualify for separate rate status, resulting in a unified tax rate of 184.26% for other exporters, although this is a reduction from the initial rate of 450.64% [2] - The high tax rates are expected to diminish Sanyuan's cost competitiveness in the U.S. market, leading to potential order reductions and market share loss [2][3] Group 2: Market Dynamics and Alternatives - The U.S. market for sweeteners is significant, with 30%-40% of beverages being imported, indicating ongoing demand despite the tariff challenges [3] - Sanyuan Biotech can explore alternative market strategies, such as changing product forms to bypass tariffs or utilizing third-party channels for U.S. market entry [4] - The company is also developing alternatives to erythritol, such as allulose, which is projected to be a strategic sweetener with lower calories and a taste profile similar to sucrose [5] Group 3: Future Prospects and Innovations - Sanyuan Biotech is focusing on technological innovation to extend its product offerings beyond traditional sugar alcohols, which are already cost-effective due to mature production processes [5] - The company aims to tap into emerging markets in Southeast Asia, India, the Middle East, and South America as part of its growth strategy [4][5]